LONDON, June 6 Visiongain issued the following pharmaceutical industry report:
Report Details
Discover the highest potential revenues in over-the-counter medicine
What does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2022, assessing data, trends, opportunities and prospects there.
This new study investigates OTC (over-the-counter) pharmaceuticals: medicines sold without prescriptions. It lets you assess projected sales at world market, therapeutic submarket, product and national level to 2022. You discover high growth potential there.
You see forecasting of five world-level submarkets to 2022, finding potential revenues:
* Analgesics/pain relievers
* Gastrointestinal agents
* Dermatological treatments
* Smoking cessation products
* Other relevant sales in consumer healthcare.
The analyses exclude vitamins, minerals and other nutritional products.
Also, how will eight leading products - including Tylenol, Nicorette, Panadol and Advil - perform from 2012 to 2022? Our investigation gives you business research and analysis with sales forecasts, including revenues for three leading OTC brand portfolios to 2022.
You find discussion of manufacturing and distribution of OTC pharmaceuticals. We also discuss regulations in main regions - the US, Europe, Japan and other places.
Our report lets you assess Rx-to-OTC switching too. You see trends and outlooks for line extensions of prescription drugs:
* Cough, cold and allergies
* Pain relief, including arthritis pains
* Gastrointestinal disorders
* Dermatological conditions
* Obesity and weight loss
* Oral contraceptives
* Cholesterol lowering
* Triptans
* Erectile dysfunction
* Sleep disorders.
We discuss other aspects of the industry and market, including Web 2.0 marketing. You find discussions of brand identity and private labels, as well as developments in OTC retail channels, including behind-the-counter and pharmacy-only sales.
Market value for 2014 and future prospects in consumer healthcare
What will happen next? There is a trend for drugs to move from prescription-only to OTC use (Rx-to-OTC switching) in product lifecycle management (PLM).
Overall world revenue for OTC medicines will reach $80.7bn in 2014, our report forecasts. Brand line extensions and PLM will be important, stimulating revenue generation and unit sales worldwide. You see high revenue growth possible to 2022.
From 2012 onwards, Rx-to-OTC switching and emerging healthcare markets - especially in Asia and Latin America - will produce high sales growth and large revenues. The pharma industry will benefit, as will consumers.
There are high levels of self-medication for many ailments. OTC treatments help consumers and healthcare providers reduce medical costs. Our study shows you the potential those products hold.
From 2012 to 2022, the pharmaceutical industry will develop new OTC treatments; our analyses predict strong revenue growth overall. New formulations and generics will be important to the world market. You see opportunities in consumer healthcare.
What are companies doing? Our work profiles 11 organisations, investigating activities and prospects of the industry. You assess these companies:
* Johnson & Johnson
* Sanofi
* GlaxoSmithKline
* Novartis
* Bayer
* Pfizer
* Boehringer Ingelheim
* Perrigo
* Merck & Co.
* Reckitt Benckiser
* Procter & Gamble.
Product launches and strong performance from some existing brands will stimulate the market this decade. Marketing and promotional campaigns remain important.
What effects will competition have? Brand extensions and OTC switching will change the industry. Our investigation shows you revenue prospects for OTC markets, leading products and portfolios. Many opportunities remain, with high, fast-rising sales possible to 2022.
Forecasts, market shares, developmental trends, commercial news and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles, R&D and commercial developments. You receive 60 tables, 35 charts and two research interviews.
Nine ways World OTC Pharmaceutical Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
* Find potential revenues to 2022 for the overall world market and submarkets
* Discover projected revenues of leading products and OTC portfolios to 2022
* See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
* Assess 11 leading companies, and others, discovering activities and outlooks
* Review prospects for Rx-to-OTC switching by therapeutic area
* Investigate competition and opportunities influencing sales
* Find out what will stimulate and restrain the industry and market
* Analyse prospects for established companies and those seeking to enter the sector
* View opinions from our survey, seeing interviews with authorities.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.
Gain research and analysis now for consumer healthcare
Our study is for everybody needing industry and market analyses for OTC pharma products. You find data, predictions and answers there. Please order that report now.
TNS C-AmbRan 120607-mt93-3901119 61MarlizTagarum
